The acquisition is subject to direct sputum sample acquisition of the M.tuberculosis nucleic acid and rifampicin resistance (MTB+RIF) demonstration test for units of HUSLAB and ISLAB and the isoniazide resistance assay INH (if not included in the MTB+RIF test) ta HUSLAB. In addition, the purchase will be subject to the lease of the equipment needed to carry out the tests at the HUSLAB Helsinki office.

HUS Diagnostic Centre conducts diagnostics based on the demonstration of nucleic acid for tuberculosis at HUSLAB's Helsinki and Lappeenranta offices. ISLAB conducts diagnostics at the Kuopio office. For M.tuberculosis complex nucleic acid and rifampicin resistance (MTB+RIF), the estimated sample amount for HUSLAB is approximately 2600 to 3000 tests/year, of which more than 95% are analysed in Helsinki and ISLAB has an estimated sample count of approximately 650 to 750 tests/year. It is also estimated that the genotypic resistance assay of isoniazide is performed directly from the sample at HUSLAB at approximately 100 pcs/year.

The acquisition is divided into two subdivisions:

Subdivision 1: Tuberculosis nucleic acid demonstration tests and equipment for HUSLAB

Subdivision 2: Tests for tuberculosis nucleic acid for ISLAB and HUSLAB Lappeenranta

The bidder may submit an offer in either one or both of the above subdivisions. Both subdivisions are individually compared and one (1) Vendor is selected for both subdivisions. If the provider offers both subdivisions, the test price for M.tuberculosis complex nucleic acid and rifampicin resistance (MTB+RIF) shall be the same in both areas due to the Subscriber's subscription system.

The object of the acquisition and its requirements are described in detail in the call for tender and its annexes.

Subdivision 1:

The main focus of the acquisition is the acquisition of the M.tuberculosis complex nucleic acid and rifampicin resistance (MTB+RIF) demonstration test HUSLAB Helsinki and the isoniazide resistance assay INH (if not included in the MTB+RIF test) acquisition. In addition, the acquisition is subject to the lease of adequate equipment needed to conduct the tests at the HUSLAB Helsinki office. The tests offered must be suitable for the equipment provided.

The capacity of the equipment shall be sufficient to obtain sample results, if necessary, in Helsinki 8 displays per 2 h. The equipment must be able to perform TB nucleic acid demonstration and rifampicin and isoniazide resistance assay. The hardware must consist of at least two devices independent of each other and be mounted on the table. The status requirement for the entire hardware on the table shall not exceed 80cm x 240cm. In providing adequate equipment, the provider may take into account Huslab/Helsinki 1 pc GenExpert (4 test slots) equipment already available to the subscriber or provide equipment suitable for testing.

The device can also run other studies every year and the device serves as a backup device for other studies as well. Therefore, it is difficult to estimate the total annual sample volume or the total consumption of the equipment bound supplies required for the device.

Offer prices are requested separately for tests and equipment. The test price shall include the necessary test kittes, controls, calibrators, test-specific software, shipping costs and product support. The device is rented at a monthly rent. The price includes all components required for use in accordance with the purpose of the hardware (such as computer, monitor, printer, programs and licenses), as well as delivery, installations, operational training and periodic maintenance of the hardware.

The subscriber chooses one (1) vendor with which it enters into a lease on hardware and a contract on tests. The contracts will be valid for a fixed term of 3 years, after which they will continue for indefinite periods of contract. The contract period begins when both sides have signed an agreement.

The device can be redeemed for HUSLab. The redemption price of the device is the residual value at the time of redemption. The residual value is calculated using an amortisation period of five (5) years. The subscriber has the right to take a service contract for the device.

The object of the acquisition and its requirements are described in detail in the call for tender and its annexes.

Section 2

The acquisition is the acquisition of the M.tuberculosis complex nucleic acid and rifampicin resistance (MTB+RIF) demonstration test for HUSLAB Lappeenranta unit and ISLAB units.

The test price shall include the necessary test kittes, controls, calibrators, test-specific software, shipping costs and product support. The tests should be suitable for existing GenExpert hardware in the procurement unit's laboratory.

The subscriber chooses one (1) vendor with which it contracts. The contract will be valid for a fixed term of 3 years, after which it will continue for the indefinite period of contract. The contract period begins when both sides have signed an agreement.